The weight gain and metabolic dysfunction has been vital conditions for individuals with schizophrenia. rTMS is a promising novel intervention, which have strong potentials on moderating increased appetite and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of rTMS, using iTBS pattern, on prevention and treatment for elevated appetite and cognitive deficiency in individual with schizophrenia.
The weight gain and metabolic dysfunction has been vital conditions for individuals with schizophrenia. The cognitive function deficit has also been a major symptom for schizophrenia. However, metabolic dysfunction could further impair the cognition. rTMS is a promising novel intervention, which have strong potentials on moderating increased appetite and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of rTMS, using iTBS pattern, on prevention of the elevated appetite and cognitive deficiency in individual with schizophrenia. The intervention will last for 5 continuous days and the follow-ups are scheduled at baseline, 6days and 36days. The primary outcomes include the change of MCCB score, TFEQ score and EEG data. Secondary outcomes include the change of serum metabolic indexes and anthropometry indexes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
10
Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
TMS coil vertical to the brain surface, with same protocol as iTBS
Central South University
Changsha, Hunan, China
Change of Appetite
Three-Factor Eating Questionnaire
Time frame: Change from Baseline to 6days and 36days
Change of MCCB
The MATRICS™ Consensus Cognitive Battery
Time frame: Change from Baseline to 6days and 36days
Change of ERP
Food picture ERP recorded by EEG
Time frame: Change from Baseline to 6days and 36days
Change of fasting glucose
in mmol/l
Time frame: Change from Baseline to 6days and 36days
Change of fasting insulin level
in mmol/l
Time frame: Change from Baseline to 6days and 36days
Change of Triglyceride
in mmol/l
Time frame: Change from Baseline to 6days and 36days
Change of Total Cholesterol
in mmol/l
Time frame: Change from Baseline to 6days and 36days
Change of LDL
in mmol/l
Time frame: Change from Baseline to 6days and 36days
Change of HDL
in mmol/l
Time frame: Change from Baseline to 6days and 36days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change of BMI
weight and height will be combined to report BMI in kg/m\^2
Time frame: Change from Baseline to 6days and 36days